NEI may resolve Avastin-Lucentis debate

Why This Topic Matters

The topic is relevant because changes in drug approval, coverage, and payment policy can directly affect ophthalmology billing, patient cost-sharing, and payer reimbursement practices.

Article Sections

1. NEI study and coverage debate

   Introduces the National Eye Institute effort and explains the broader treatment and reimbursement controversy in ophthalmology. It frames the article around safety, effectiveness, and payer interest.

2. Pricing, payer reaction, and patient impact

   Describes the market and coverage response after the newer drug approval and notes the implications for patient access and reimbursement attention. It also places the discussion in the context of Medicare and carrier behavior.

3. J-code choices

   Summarizes the billing codes referenced for the drugs discussed and notes that no dedicated ophthalmic billing code was available at the time. This section focuses on claim submission context for practices and payers.

4. Background

   Provides general historical context on carrier coverage, off-label use, and the relationship between approval status and billing considerations. It also explains how the article situates earlier practice patterns against the newer approval environment.